Business
Helix BioPharma Corp. Announces Fiscal 2023 Third Quarter Results
(TheNewswire) Toronto, Ontario – TheNewswire – June 14, 2023 - He...
About this update from Helix Biopharma Corp.
[{"type":"text","content":"Helix BioPharma Corp. Announces Fiscal 2023 Third Quarter Results\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Toronto, Ontario –\n \n \n \n \n TheNewswire – June 14, 2023 -\n \n \n Helix BioPharma Corp.\n \n \n (TSX:HBP), (“\n \n \n Helix\n \n \n ” or the “\n \n \n Company\n \n \n ”), a\nclinical-stage biopharmaceutical company developing unique therapies\nin the field of immuno-oncology based on its proprietary technological\nplatform DOS47, today announced financial results for the fiscal 2023\nthird quarter results for the period ending April 30, 2023.\n \n \n \n \n OVERVIEW\n \n \n \n \n The Company reported a net loss and total comprehensive\nloss of $1,337,000 and $4,136,000 for the three and nine-month periods\nended April 30, 2023, respectively (April 30, 2022 - $1,345,000 and\n$5,177,000) and a loss of $0.01 and $0.01 per common share\nrespectively (April 30, 2022– loss of $0.01 and $0.04 per common\nshare).\n \n \n \n \n Clinical\ndevelopment\n \n \n \n \n LDOS47 in lung cancer\n \n \n \n \n Ø  The Phase I study combination therapy in lung\ncancer (LDOS001) was completed and a manuscript was accepted for\npublication in\n \n \n Journal of\nThoracic Oncology Clinical and Research Reports\n \n \n on September 2\n \n \n nd\n \n \n , 2022. The full-text open access\narticle can be found here:\n \n \n \n \n https://www.jtocrr.org/article/S2666-3643(22)00132-1/fulltext\n \n \n \n \n .\n \n \n \n \n Ø  The Phase II study of combination therapy in lung\ncancer (LDOS003) was halted in the dose escalation portion of the\nstudy in 2020 at the height of pandemic lockdown and the final\nabbreviated clinical trial report has been further delayed amidst war\nin Ukraine where all subjects were recruited. The company is\ncurrently working with study partners to retrieve any data that is\nsalvageable and conclude the study by the end of the third quarter of\n2023.\n \n \n \n \n Ø  Another important aspect of the development of\nthe LDOS47 platform is the combination with chemo- and/or\nimmuno-therapy to enhance current therapies, that may boost the\nutility of the platform. The Company continues\nto have engaged several key opinion leaders to evaluate potential\ncombi...